Life Sciences Tools and Services
Company Overview of Celerion, Inc.
Celerion, Inc. provides early stage clinical research solutions. It offers global clinical research solutions, such as Phase 0, I and IIa, and NDA-enabling clinical pharmacology study; clinical pharmacology science services that include modeling and simulation, study design and protocol development, data programming, biostatistics, pharmacokinetics/pharmacodynamics, medical writing and reporting, and drug development; global bioanalytical services ranging from method development and validation through rapid sample analysis supporting discovery through late stage clinical trials; and drug development services, which include program and project management, regulatory, and drug development cons...
621 Rose Street
Lincoln, NE 68502
Key Executives for Celerion, Inc.
Chief Executive officer and President
Chief Cardiologist and Global Medical Director of Cardiac Safety Services
Vice President of Global Business Development
Vice President of Global Bioanalytical Services
Compensation as of Fiscal Year 2014.
Celerion, Inc. Key Developments
Celerion Appoints Robert Lester as Chief Cardiologist, Global Medical Director of Cardiac Safety Services
Jun 16 14
Celerion announced the appointment of Robert Lester MD FACC, as Chief Cardiologist, Global Medical Director of Cardiac Safety Services. Dr. Lester will develop and lead Celerion's strategic vision in Cardiac Safety Services. He will be based in the facility in Phoenix, Arizona. Dr. Lester comes to Celerion with over 25 years experience in clinical medicine and academia, as well as over 13 years experience as a Director and Senior Cardiologist at several Contract Research Organizations (CROs) and ECG Core labs. Dr. Lester will utilize his extensive experience and expertise in the area of cardiac safety, to provide advice and lead client programs. He will also be a driving force for Celerion's innovative Highly Automated ECG Core Lab that enables clients to expedite ECG review, thereby significantly reducing the time and cost for cardiac safety studies over traditional approaches.
Foundation for the National Institutes of Health Selects Celerion to Provide Clinical Recruitment and Conduct to Support the Beta Cell Project
Jun 11 14
Celerion announced that it has been selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to provide clinical support for The Beta Cell Project. The Beta Cell Project is a program of studies designed to standardize biomarker measures of beta cell function. Celerion will provide clinical recruitment and conduct to support The Beta Cell Project and assist the FNIH in developing pharmacodynamic measures of beta cell function, with the goal to create industry standards.
Celerion Establishes Business Presence in Singapore; Appoints Chew Lan Chong as Executive Director, Medical Research
Jun 4 14
Celerion announced the expansion of a formal business presence in Singapore. The opening of the Singapore operations and appointment of Dr. Chong follows quickly after the recent announcements of Celerion's expansion into South Korea. The expansion to Singapore and South Korea enables Celerion to provide access for clients to perform innovative and informative early clinical research studies in Asian patients and healthy participants.
Heading up the new operations in Singapore is Dr. Chew Lan Chong, MBBS, MRCS, MSc as Executive Director, Medical Research. Dr. Chong brings 10 years of direct operational experience leading clinical pharmacology units. Dr. Chong will lead Celerion's business operations in Singapore, provide medical and scientific expertise and collaborate with partner early clinical research units to conduct complex early clinical pharmacology studies to the high global standards.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|